These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 18045731)
1. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Johnson EA; Marks RS; Mandrekar SJ; Hillman SL; Hauge MD; Bauman MD; Wos EJ; Moore DF; Kugler JW; Windschitl HE; Graham DL; Bernath AM; Fitch TR; Soori GS; Jett JR; Adjei AA; Perez EA Lung Cancer; 2008 May; 60(2):200-7. PubMed ID: 18045731 [TBL] [Abstract][Full Text] [Related]
2. Randomized, double-blind, placebo-controlled phase II study of single-agent oral talactoferrin in patients with locally advanced or metastatic non-small-cell lung cancer that progressed after chemotherapy. Parikh PM; Vaid A; Advani SH; Digumarti R; Madhavan J; Nag S; Bapna A; Sekhon JS; Patil S; Ismail PM; Wang Y; Varadhachary A; Zhu J; Malik R J Clin Oncol; 2011 Nov; 29(31):4129-36. PubMed ID: 21969509 [TBL] [Abstract][Full Text] [Related]
3. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale). Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G; Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419 [TBL] [Abstract][Full Text] [Related]
4. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I. Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154 [TBL] [Abstract][Full Text] [Related]
6. Phase III trial comparing carboplatin, paclitaxel, and bexarotene with carboplatin and paclitaxel in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT II. Blumenschein GR; Khuri FR; von Pawel J; Gatzemeier U; Miller WH; Jotte RM; Le Treut J; Sun SL; Zhang JK; Dziewanowska ZE; Negro-Vilar A J Clin Oncol; 2008 Apr; 26(11):1879-85. PubMed ID: 18398153 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. Schiller JH; Larson T; Ou SH; Limentani S; Sandler A; Vokes E; Kim S; Liau K; Bycott P; Olszanski AJ; von Pawel J J Clin Oncol; 2009 Aug; 27(23):3836-41. PubMed ID: 19597027 [TBL] [Abstract][Full Text] [Related]
8. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. Butts C; Murray N; Maksymiuk A; Goss G; Marshall E; Soulières D; Cormier Y; Ellis P; Price A; Sawhney R; Davis M; Mansi J; Smith C; Vergidis D; Ellis P; MacNeil M; Palmer M J Clin Oncol; 2005 Sep; 23(27):6674-81. PubMed ID: 16170175 [TBL] [Abstract][Full Text] [Related]
9. Phase III trial of two versus four additional cycles in patients who are nonprogressive after two cycles of platinum-based chemotherapy in non small-cell lung cancer. Park JO; Kim SW; Ahn JS; Suh C; Lee JS; Jang JS; Cho EK; Yang SH; Choi JH; Heo DS; Park SY; Shin SW; Ahn MJ; Lee JS; Yun YH; Lee JW; Park K J Clin Oncol; 2007 Nov; 25(33):5233-9. PubMed ID: 18024869 [TBL] [Abstract][Full Text] [Related]
10. Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: a double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group. Koch A; Bergman B; Holmberg E; Sederholm C; Ek L; Kosieradzki J; Lamberg K; Thaning L; Ydreborg SO; Sörenson S; Eur J Cancer; 2011 Jul; 47(10):1546-55. PubMed ID: 21565487 [TBL] [Abstract][Full Text] [Related]
11. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. Pujol JL; Breton JL; Gervais R; Tanguy ML; Quoix E; David P; Janicot H; Westeel V; Gameroff S; Genève J; Maraninchi D J Clin Oncol; 2007 Sep; 25(25):3945-51. PubMed ID: 17761978 [TBL] [Abstract][Full Text] [Related]
12. Enzastaurin, an oral serine/threonine kinase inhibitor, as second- or third-line therapy of non-small-cell lung cancer. Oh Y; Herbst RS; Burris H; Cleverly A; Musib L; Lahn M; Bepler G J Clin Oncol; 2008 Mar; 26(7):1135-41. PubMed ID: 18309949 [TBL] [Abstract][Full Text] [Related]
13. Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901. Stadler WM; Rosner G; Small E; Hollis D; Rini B; Zaentz SD; Mahoney J; Ratain MJ J Clin Oncol; 2005 Jun; 23(16):3726-32. PubMed ID: 15923569 [TBL] [Abstract][Full Text] [Related]
14. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Greco FA; Bonomi P; Crawford J; Kelly K; Oh Y; Halpern W; Lo L; Gallant G; Klein J Lung Cancer; 2008 Jul; 61(1):82-90. PubMed ID: 18255187 [TBL] [Abstract][Full Text] [Related]
15. Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. Blumenschein GR; Gatzemeier U; Fossella F; Stewart DJ; Cupit L; Cihon F; O'Leary J; Reck M J Clin Oncol; 2009 Sep; 27(26):4274-80. PubMed ID: 19652055 [TBL] [Abstract][Full Text] [Related]
16. Effects of erlotinib first-line maintenance therapy versus placebo on the health-related quality of life of patients with metastatic non-small-cell lung cancer. Juhász E; Kim JH; Klingelschmitt G; Walzer S Eur J Cancer; 2013 Apr; 49(6):1205-15. PubMed ID: 23477998 [TBL] [Abstract][Full Text] [Related]
17. Randomized, phase III study of weekly paclitaxel in combination with carboplatin versus standard every-3-weeks administration of carboplatin and paclitaxel for patients with previously untreated advanced non-small-cell lung cancer. Belani CP; Ramalingam S; Perry MC; LaRocca RV; Rinaldi D; Gable PS; Tester WJ J Clin Oncol; 2008 Jan; 26(3):468-73. PubMed ID: 18202422 [TBL] [Abstract][Full Text] [Related]
18. Weekly administration of epoetin beta for chemotherapy-induced anemia in cancer patients: results of a multicenter, Phase III, randomized, double-blind, placebo-controlled study. Tsuboi M; Ezaki K; Tobinai K; Ohashi Y; Saijo N Jpn J Clin Oncol; 2009 Mar; 39(3):163-8. PubMed ID: 19164318 [TBL] [Abstract][Full Text] [Related]
19. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small cell lung cancer. Peschel C; Hartmann JT; Schmittel A; Bokemeyer C; Schneller F; Keilholz U; Buchheidt D; Millan S; Izquierdo MA; Hofheinz RD Lung Cancer; 2008 Jun; 60(3):374-80. PubMed ID: 18054408 [TBL] [Abstract][Full Text] [Related]
20. The role of maintenance chemotherapy in advanced nonsmall cell lung cancer. Jalal SI; Ademuyiwa FO; Hanna NH Curr Opin Oncol; 2009 Mar; 21(2):110-5. PubMed ID: 19532011 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]